Lecap Asset Management Ltd. Purchases New Stake in Labcorp Holdings Inc. $LH

Lecap Asset Management Ltd. acquired a new stake in Labcorp Holdings Inc. (NYSE:LH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,087 shares of the medical research company’s stock, valued at approximately $774,000.

Other hedge funds also recently modified their holdings of the company. Victory Capital Management Inc. lifted its holdings in shares of Labcorp by 20.0% during the third quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after buying an additional 440,224 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of Labcorp by 4,070.6% in the third quarter. Pacer Advisors Inc. now owns 305,746 shares of the medical research company’s stock valued at $87,767,000 after acquiring an additional 298,415 shares in the last quarter. Wellington Management Group LLP increased its position in Labcorp by 15.9% during the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after acquiring an additional 289,029 shares during the period. Marshall Wace LLP increased its position in Labcorp by 79.1% during the third quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock worth $178,996,000 after acquiring an additional 275,454 shares during the period. Finally, Mondrian Investment Partners LTD acquired a new stake in Labcorp in the 3rd quarter worth about $75,208,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Activity

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares of the company’s stock, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 16,113 shares of company stock valued at $4,547,450 over the last quarter. 0.84% of the stock is owned by insiders.

Labcorp Stock Performance

LH stock opened at $270.81 on Monday. The stock has a 50-day moving average price of $273.67 and a 200-day moving average price of $268.17. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The firm has a market cap of $22.26 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 1.85 and a beta of 1.02.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the company posted $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities research analysts expect that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is 27.53%.

Analyst Ratings Changes

LH has been the subject of several recent analyst reports. Piper Sandler upped their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Robert W. Baird raised their target price on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. boosted their target price on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Wall Street Zen downgraded shares of Labcorp from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp has a consensus rating of “Moderate Buy” and a consensus target price of $307.20.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.